Alterity Therapeutics Ltd has released a press release.
ATH Annual General Meeting Presentation
Filed with ASX ·
6ix hasn’t read this filing yet.
Alterity Therapeutics Ltd. on 6ix
In the deck
Story so far
Earlier from Alterity Therapeutics
- Chairmans Address 2021 Annual General Meeting
- New Data Advance ATH434 as Neurodegeneration treatment
- Expanded ATH434 Phase 2 Clinical Development Program
- Form 20-F
- Appendix 4E & Annual Report 2021
Later from Alterity Therapeutics
- First Regulatory Authorization to Proceed with Phase 2 Trial
- New US Patent for Compounds to Treat Neurodegeneration
- Response to ASX Query
- New publication shows ATH434 rescues neurons in MSA model
- UK Regulatory Authorisation to Proceed with Phase 2 Trial
Follow Alterity Therapeutics into a list and get an email when it puts out news.
Follow Alterity Therapeutics